The 2017 LakePharma Symposium was held at the South San Francisco Conference Center on Oct. 7th.
Over 400 local scientists attended the day-long event. The 2017 program was organized by Aaron Sato (CSO) and John “Lippy” Lippincott (VP, Antibody Discovery), with speakers from local biotech companies and academic institutions, such as AbbVie, BMS, Pfizer, Genentech, UCSF, Distributed Bio and IGM Biosciences -- to name a few. The Symposium covered a broad array of topics, including antibody discovery, ADCs and bispecifics, novel targets and therapeutic modalities. In addition to formal presentations, the symposium included special topic workshops, a poster session, and a happy hour for networking.
Aaron Sato, Ph.D., CSO, LakePharma, Inc.
John "Lippy" Lippincott, Ph.D., VP of Antibody Discovery, LakePharma, Inc.
Jacob Glanville, Ph.D., CSO, Distributed Bio
Arvind Rajpal, Ph.D., VP of Protein Therapeutics, BMS
Christoph Spiess, Ph.D., Sr. Scientist, Genentech
Bruce Keyt, Ph.D., CSO, IGM BioSciences
Scott Dylla, Ph.D., VP of R&D & CSO, AbbVie Stemcentrx
Bin Liu, Ph.D., Professor, UCSF
Andy Yeung, Ph.D., Associate Research Fellow, Rinat-Pfizer
Patrick Y. Yang, Ph.D., Chairman, Acepodia & Executive Vice President, Juno Therapeutics
Download full agenda, including speaker bios and poster listings:
8:30 Breakfast and Registration
8:55 Welcome Remarks: Aaron Sato, Ph.D., CSO, LakePharma
Morning Session I: Protein Engineering and Biotechnology
9:00 – 9:30 am: Patrick Y. Yang, Ph.D., Chairman, Acepodia & Executive Vice President, Juno Therapeutics
"The trend and future of the biotech industry"
9:35 – 10:05 am: Arvind Rajpal, Ph.D, Vice President, BMS, Protein Therapeutics
"Protein engineering in oncology"
10:10-10:40 Morning Break
Morning Session II: ADCs and Bispecifics
10:40 – 11:10 am: Scott Dylla, Ph.D., Vice President of Research & Development, CSO, AbbVie Stemcentrx
"Preclinical modeling and screening strategies to improve the clinical translation of ADCs"
11:15 – 11:45 am: Christoph Spiess, Ph.D., Senior Scientist, Genentech
"Bispecific antibodies: strategies, considerations and challenges"
11:50 am – 1:00 pm: Lunch and Breakout Mini Sessions
12:30 – 1:00 pm: Breakout Mini Sessions
Breakout 1: "Latest development in high titer protein expression using ExpiCHO transient expression system"
Henry Chiou, Ph.D., Portfolio Leader for Protein Expression at Thermo Fisher
Breakout 2: “The LakePharma Antibody Technology Network (LATN) -- an introduction to using LATN to access top antibody technologies and resources”
Aaron Sato, Ph.D., CSO, LakePharma
Breakout 3: "Promega's expanding suite of bioassays for biologics"
Jamison Grailer, Ph.D., Senior Research Scientist, Promega
Breakout 4: "Nanomolar-- a disruptive marketplace platform connecting technology with investors"
Michael Benzinou, Co-founder & SVP, Nanomolar
1:05 Afternoon Session Remarks: John “Lippy” Lippincott, Ph.D., VP of Antibody Discovery, LakePharma
Afternoon Session I: Antibody Discovery
1:10 – 1:40 pm: Jacob Glanville, Ph.D., CSO, Distributed Bio
"SuperHuman-2.0: how computational immunoengineering can realize the dream of a one-week antibody discovery cycle"
1:45 – 2:15 pm: Andy Yeung, Ph.D., Associate Research Fellow, Pfizer-Rinat
“Germline-encoded neutralization of a Staphylococcus aureus virulence factor by the human antibody repertoire”
2:20 – 3:00 Poster Session and Break
Afternoon Session II: Novel Targets and Therapeutic Modalities
3:10 – 3:40 pm: Bin Liu, Ph.D., Professor, Department of Anesthesia, UCSF
"Cell surface target selection in antibody therapy development"
3:45 – 4:15 pm: Bruce Keyt, Ph.D., CSO, IgM Biosciences
“High avidity, bi-specific IgMs for cross-linking tumor targets in the treatment of cancers”
4:20 RAFFLE AND CLOSING REMARKS
4:30 - 6 Networking and Happy Hour
Thank you to our sponsors! Interested exhibitors for 2018, please contact firstname.lastname@example.org for information.
ONLINE REGISTRATION IS NOW CLOSED.
Limited space is available for onsite registration on Friday, first come, first served.
Please contact email@example.com for more information.